OBJECTIVE: This research aims to design and evaluate an enteric-coated hard capsule dosage form for targeted delivery of biological materials, such as FMT (fecal microbiota transplant) or live microbes, to the distal parts of the GIT. The capsules are designed to be internally protected against destruction by hydrophilic filling during passage through the digestive tract. METHODS: Hard gelatin capsules and DRcapsTMcapsules based on HPMC and gellan were used to encapsulate a hydrophilic body temperature-liquefying gelatin hydrogel with caffeine or insoluble iron oxide mixture. Different combinations of polymers were tested for the internal (ethylcellulose, Eudragit® E, and polyvinyl acetate) and external (Eudragit® S, Acryl-EZE®, and cellacefate) coating. The external protects against the acidic gastric environment, while the internal protects against the liquid hydrophilic filling during passage. Coated capsules were evaluated using standard disintegration and modified dissolution methods for delayed-release dosage forms. RESULTS: Combining suitable internal (ethylcellulose 1.0 %) and external (Eudragit® S 20.0 %) coating of DRcapsTM capsules with the wiping and immersion method achieved colonic release times. While most coated capsules met the pharmaceutical requirements for delayed release, one combination stood out. Colonic times were indicated by the dissolution of soluble caffeine (during 120-720 min) measured by the dissolution method, and capsule rupture was indicated by the release of insoluble iron oxide (after 480 min) measured by the disintegration method. This promising result demonstrates the composition's suitability and potential to protect the content until it's released, inspiring hope for the future of colon-targeted delivery systems and its potential for the pharmaceutical and biomedical fields. CONCLUSION: Innovative and easy capsule coatings offer significant potential for targeted drugs, especially FMT water suspension, to the GIT, preferably the colon. The administration method is robust and not considerably affected by the quantity of internal or external coatings. It can be performed in regular laboratories without specialized individual and personalized treatment equipment, making it a practical and feasible method for drug delivery.
- MeSH
- bakteriální polysacharidy chemie MeSH
- biokompatibilní materiály chemie MeSH
- celulosa * chemie analogy a deriváty MeSH
- deriváty hypromelózy chemie MeSH
- hydrofobní a hydrofilní interakce * MeSH
- hydrogely chemie MeSH
- kofein chemie aplikace a dávkování MeSH
- kolon * metabolismus MeSH
- kyseliny polymethakrylové chemie MeSH
- lékové transportní systémy * metody MeSH
- léky s prodlouženým účinkem chemie MeSH
- polymery chemie MeSH
- polyvinyly chemie MeSH
- tobolky * MeSH
- uvolňování léčiv * MeSH
- želatina * chemie MeSH
- železité sloučeniny chemie aplikace a dávkování MeSH
- Publikační typ
- časopisecké články MeSH
Růst zájmu o zdraví a snaha o jeho udržení vedou k zneužívání tohoto trendu ze strany výrobců různých léčebných přípravků. Spotřebitelé by měli být obezřetní u produktů, které nejsou registrovány jako léky, zdůrazňují svůj přírodní původ bez ohledu na rizika, deklarují absenci nežádoucích účinků, slibují vyléčení široké škály onemocnění, mají neznámé mechanismy účinku, spoléhají se na kazuistiky celebrit namísto klinických studií a opírají se o tradiční systémy medicíny bez vědeckého ověření. Přípravky jsou doporučovány osobami bez relevantní odbornosti a bývají prodávány mimo lékárny a obchodní řetězce. Jejich aplikace bez kritického posouzení může vést k zanedbání skutečné léčby, zdravotním komplikacím nebo finančním ztrátám.
The growing interest in the good state of health and the effort to maintain it leads to the abuse of this trend by manufacturers of various medical preparations. Consumers should be wary of products, the producers of which do not register them as drugs, emphasize their natural origin regardless of risks, declare the absence of side effects, promise to cure a wide range of diseases, do not present mechanisms of action, rely on case reports of celebrities instead of clinical studies, and on traditional systems of medicine without scientific verification. Products recommended by individuals without relevant expertise are often being sold outside the pharmacies and retail chains. Their application without critical assessment can lead to neglecting the treatment, health complications, or financial losses.
Probiotics have been used in human and veterinary medicine to increase resistance to pathogens and provide protection against external impacts for many years. Pathogens are often transmitted to humans through animal product consumption. Therefore, it is assumed that probiotics protecting animals may also protect the humans who consume them. Many tested strains of probiotic bacteria can be used for individualized therapy. The recently isolated Lactobacillus plantarum R2 BiocenolTM has proven to be preferential in aquaculture, and potential benefits in humans are expected. A simple oral dosage form should be developed to test this hypothesis by a suitable preparation method, i.e., lyophilization, allowing the bacteria to survive longer. Lyophilizates were formed from silicates (Neusilin® NS2N; US2), cellulose derivates (Avicel® PH-101), and saccharides (inulin; saccharose; modified starch® 1500). They were evaluated for their physicochemical properties (pH leachate, moisture content, water absorption, wetting time, DSC tests, densities, and flow properties); their bacterial viability was determined in conditions including relevant studies over 6 months at 4 °C and scanned under an electron microscope. Lyophilizate composed of Neusilin® NS2N and saccharose appeared to be the most advantageous in terms of viability without any significant decrease. Its physicochemical properties are also suitable for capsule encapsulation, subsequent clinical evaluation, and individualized therapy.
- Publikační typ
- časopisecké články MeSH
Currently, there is a growing need to prepare small batches of enteric capsules for individual therapy or clinical evaluation since many acidic-sensitive substances should be protected from the stomach's acidic environment, including probiotics or fecal material, in the fecal microbiota transplantation (FMT) process. A suitable method seems to be the encapsulation of drugs or lyophilized alternatively frozen biological suspensions in commercial hard enteric capsules prepared by so-called Enteric Capsule Drug Delivery Technology (ECDDT). Manufacturers supply these types of capsules, made from pH-soluble polymers, in products such as AR Caps®, EnTRinsicTM, and Vcaps® Enteric, or capsules made of gelling polymers that release their content as the gel erodes over time when passing through the digestive tract. These include DRcaps®, EMBO CAPS® AP, BioVXR®, or ACGcapsTM HD. Although not all capsules in all formulations meet pharmaceutical requirements for delayed-release dosage forms in disintegration and dissolution tests, they usually find practical application. This literature review presents their composition and properties. Since ECDDT is a new technology, this article is based on a limited number of references.
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Pharmaceutical technology offers several options for protecting substances from acidic environments, such as encapsulation in enteric capsules or dosage form with enteric coating. However, commercial enteric capsules do not always meet limits for pharmacopeial delayed release, and the coating process is generally challenging. Preparing small enteric batches suitable for clinical use is, therefore, an unsolved problem. This experiment offers a simple coating process of DRcapsTM capsules based on hypromellose (HPMC) and gellan gum to achieve small intestine administration. In addition, DRcapsTM capsules were compared to hard gelatin capsules to evaluate the suitability of the coating method. Both capsules were immersed in dispersions of Eudragit® S 100, Acryl-EZE®, and Cellacefate at concentrations of 10.0, 15.0, and 20.0% and dried. Coated capsules were evaluated by electron microscopy, disintegration, and dissolution test with a two-step pH change (from 1.2 to 6.8, then to 7.5) to simulate passage through the digestive tract. DRcapsTM capsules coated with Eudragit® S and Cellacefate achieved acid resistance. While samples coated with Eudragit® S released their contents within 360 min at pH 6.8 (small intestine), regardless of polymer concentration, capsules with 15.0 and 20.0% coatings of Cellacefate released content at pH 7.5 (colon) within 435 and 495 min, respectively.
- Publikační typ
- časopisecké články MeSH
The growing need for processing natural lipophilic and often volatile substances such as thymol, a promising candidate for topical treatment of intestinal mucosa, led us to the utilization of solid-state nuclear magnetic resonance (ss-NMR) spectroscopy for the rational design of enteric pellets with a thymol self-emulsifying system (SES). The SES (triacylglycerol, Labrasol®, and propylene glycol) provided a stable o/w emulsion with particle size between 1 and 7 μm. The ex vivo experiment confirmed the SES mucosal permeation and thymol delivery to enterocytes. Pellets W90 (MCC, Neusilin®US2, chitosan) were prepared using distilled water (90 g) by the M1-M3 extrusion/spheronisation methods varying in steps number and/or cumulative time. The pellets (705-740 μm) showed mostly comparable properties-zero friability, low intraparticular porosity (0-0.71%), and relatively high density (1.43-1.45%). They exhibited similar thymol release for 6 h (burst effect in 15th min ca. 60%), but its content increased (30-39.6 mg/g) with a shorter process time. The M3-W90 fluid-bed coated pellets (Eudragit®L) prevented undesirable thymol release in stomach conditions (<10% for 3 h). A detailed, ss-NMR investigation revealed structural differences across samples prepared by M1-M3 methods concerning system stability and internal interactions. The suggested formulation and methodology are promising for other lipophilic volatiles in treating intestinal diseases.
- Publikační typ
- časopisecké články MeSH
Výskum probiotík pre akvakultúru je v ranom štádiu a pre ich implementáciu je potrebné vykonať ešte množstvo experimentov. Laktiplantibacily patria medzi mikroorganizmy, ktoré sa najčastejšie používajú na prípravu probiotických preparátov. Doterajšie výsledky nie sú postačujúce, práve preto sú potrebné ďalšie štúdie. Výber probiotík pre akvakultúru a ich vývoj pre komerčné využitie v akvakultúre je mnohostupňový a multidisciplinárny proces vyžadujúci si v prvej etape základný a neskôr aj aplikovaný výskum a posúdenie jeho použitia v praxi. Cieľom štúdie bolo pripraviť probiotické krmivo pre ryby s využitím pomocných látok a následne sledovať prežívateľnosť probiotických bakteriálnych buniek v krmive počas 9-mesačného skladovania pri chladničkovej (4 °C) a izbovej teplote (22 °C). Na prípravu krmiva bol použitý kmeň Lactobacillus plantarum R2 Biocenol™ (CCM 8674) (podľa novej taxonómie Lactiplantibacillus plantarum), potenciálne využiteľný pre probiotické účely v akvakultúre. Lepšia prežívateľnosť probiotických bakteriálnych buniek bola zaznamenaná vo vzorkách krmiva A (Aquatex 41 HMD) v porovnaní so vzorkami probiotických peliet B (Inicio 918-2). Keďže oxidácia mastných kyselín v krmive ovplyvňuje nutričnú kvalitu jednotlivých komponentov krmiva, predpokladáme, že vyššie množstvo oleja v krmive B negatívne ovplyvnilo prežívateľnosť probiotických bakteriálnych buniek. Najvyššie počty životaschopných probiotických baktérií boli zaznamenané pri 4 °C skladovania krmiva. Po 9 mesiacoch skladovania pri chladničkovej teplote počty laktiplantibacilov vo vzorkách krmiva A klesli z hodnoty 7,30 log10KTJ/g na počet 5,57 log10KTJ/g. Teplota je považovaná za rozhodujúci faktor ovplyvňujúci životaschopnosť a prežívateľnosť probiotických baktérií počas doby skladovania.
Research in probiotics for aquaculture is at an early stage of development and much work is still needed. Lactiplantibacilli belong to the microorganisms most frequently used to prepare the probiotics. The available information is inconclusive, since few experiments with sufficiently robust design have been conducted to permit critical evaluation. The development of probiotics applicable to commercial use in aquaculture is a multistep and multidisciplinary process requiring both empirical and fundamental research, full-scale trials, and an economic assessment of its use. The aim of the study was to prepare a probiotic aquafeed via excipients and subsequently to observe the survival of probiotic bacterial cells in the feed during the nine months storage period at a refrigerator (4 °C) or room temperature (22 °C). The strain Lactobacillus plantarum R2 Biocenol™ (CCM 8674) (according to the new taxonomy Lactiplantibacillus plantarum), potentially usable as a probiotic in aquaculture, was administered to prepare the aquafeed. Better survival of probiotic bacterial cells was recorded in a samples of pellets A (Aquatex 41 HMD) compared to the samples of probiotic pellets B (Inicio 918-2). Since oxidation of fatty acids in feed affects the nutritional quality of individual feed components, we assume that higher amounts of oil in feed B negatively affected the survival of probiotic bacterial cells. The highest numbers of viable probiotic bacteria cells were recorded at 4 °C storage of probiotic feed samples. The number of lactiplantibacilli dropped from 7.30 log10CFU . g–1 to 5.57 log10CFU . g–1 after the nine months storage period of feed samples A at 4 °C. Temperature is considered as a critical factor influencing probiotic viability and survival during storage period.
V současné době existuje eminentní zájem států na proočkovanosti obyvatelstva proti COVID-19. V České republice k tomuto účelu slouží podmínečně registrované genové mRNA a vektorové DNA vakcíny, u kterých zatím absentují úplné a dlouhodobé údaje o bezpečnosti. Vakcíny vykazují řadu potenciálních rizik, jako je pronikání lipidických nanočástic do okolních tkání, zabudování DNA do hostitelského genomu, ADE syndrom, vznik rezistentních mutací, myokarditida, perikarditida a tromboembolické příhody. Vzhledem k tomu, že hladina protilátek po vakcinaci brzy klesá, imunita po prodělání nemoci je trvalejší a smrtnost nemoci je zejména u mladistvých velmi nízká, je z etického pohledu přijatelné jen dobrovolné očkování, a to bez případných přímých i nepřímých restrikcí pro neočkované. Tento závěr je v souladu s principy lékařské etiky nonmaleficence, beneficence, autonomie a spravedlnosti.
In the current context, there is an extraordinary interest of states in vaccinating the population to prevent Covid-19. In the Czech Republic, gene mRNA and vector DNA vaccines are approved only with conditional marketing authorization, for which a complete and long-term safety assessment is currently lacking. Vaccines show some potential risks, such as penetration of lipid nanoparticles into surrounding tissues, incorporation of DNA into the host genome, ADE syndrome, development of resistant mutations, myocarditis, pericarditis, and thromboembolic events. Since the level of antibodies after vaccination is soon decreasing, immunity after the disease persists longer, and the disease's fatality rate is very low, especially in adolescents, only voluntary vaccination is ethically acceptable, without any direct or indirect restrictions on the unvaccinated. The conclusion is in line with the principles of medical ethics of nonmaleficence, beneficence, autonomy, and justice.
- MeSH
- COVID-19 prevence a kontrola MeSH
- DNA vakcíny genetika imunologie škodlivé účinky MeSH
- hodnocení rizik MeSH
- lidé MeSH
- messenger RNA genetika imunologie škodlivé účinky MeSH
- nežádoucí účinky léčiv MeSH
- schvalování léčiv MeSH
- vakcinace * etika MeSH
- vakcíny proti COVID-19 * genetika imunologie škodlivé účinky MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- přehledy MeSH
OBJECTIVES: We tested the toxicity of ethinylestradiol, a semisynthetic estrogen used in oral contraceptives, on all-male triploid zebrafish using commercial feeds and three different doses concentrations. We aimed to determine whether ethinylestradiol peroral administration resulted in vitellogenin production and whether all-male triploid zebrafish could serve as a model species for xenoestrogen testing. METHODS: The actual concentrations of 17α-ethinylestradiol were 0.0035 (low); 0.0315 (medium) and 0.365 (high) μg/g. Positive control represented commercial feeds containing 0.0465 μg/g of β-estradiol. The experiment lasted 8 weeks. RESULTS: Our results indicate that 17α-ethinylestradiol consumption does induce vitellogenin production in triploid zebrafish. CONCLUSIONS: The simple presence of vitellogenin is a definite symptom indicative of the potential for such changes due to the action of estrogenic substances. As such, this experiment has shown that the use of all-male triploid zebrafish populations, rather than the mixed-sex populations of other species previously used, could serve as a suitable alternative model population for controlled testing of the effects of xenoestrogens on fish.
The aim of this study was to reveal the effects of foodborne fluoxetine on morphological and condition profile, hematological profile, biochemical and oxidative stress indices on juvenile rainbow trout. The study was performed according to OECD Guideline No. 215. Fluoxetine was incorporated into Biomar 921 pellets at a dose of 0.047 mg/kg (environmental concentration), 0.577 mg/kg and 6.7 mg/kg. There was statistically significant change in hematological profile, including an increasing trend in neutrophil/lymphocyte ratio and a decreasing trend in the number of lymphocytes. Measurements of oxidative stress indicated decreased activity of the detoxifying enzyme glutathione-S-transferase in the liver and kidney. However, the measurement of GR, GPx, CAT, SOD activity, and TBARS showed no changes. Histopathological examination revealed damage to the proximal tubules of caudal kidney in exposed groups. This study confirms that fluoxetine has a significant effect on immune response.
- MeSH
- antidepresiva druhé generace toxicita MeSH
- chemické látky znečišťující vodu toxicita MeSH
- fluoxetin toxicita MeSH
- imunita účinky léků MeSH
- kontaminace potravin MeSH
- krevní obraz MeSH
- krmivo pro zvířata MeSH
- Oncorhynchus mykiss krev imunologie MeSH
- oxidační stres účinky léků MeSH
- proximální tubuly ledvin účinky léků MeSH
- zvířata MeSH
- Check Tag
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
